gynaecological cancer

News

Data backs GSK's ovarian cancer blockbuster hopes

GSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.

News

Corcept gets FDA OK for first-in-class ovarian cancer drug

Corcept shares surge on FDA approval of Lifyorli, a first-in-class selective glucocorticoid receptor antagonist for ovarian cancer.

News

UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo

News

ImmunoGen ELAHERE wins accelerated FDA approval for ovarian ...

ImmunoGen, Inc.

Views & Analysis

ESMO 2022 – PAOLA-1, ovarian cancer, and treatment innovatio...

Last month, pharmaphorum had the chance to speak with Dr Isabelle Ray-Coquard, professor of medical oncology (specialism sarcomas and GISTs) at the Centre Léon Bérard (CLB), a hospital 100%

Data backs GSK's ovarian cancer blockbuster hopes

Corcept gets FDA OK for first-in-class ovarian cancer drug

UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer

ImmunoGen ELAHERE wins accelerated FDA approval for ovarian ...

ESMO 2022 – PAOLA-1, ovarian cancer, and treatment innovatio...

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

gynaecological cancer

Editor's Picks